AB-836

AB-836 is an orally active small molecule drug developed as a next-generation hepatitis B virus (HBV) capsid inhibitor. It targets the HBV core protein, which is essential for viral replication and the formation of functional viral capsids. By binding to a novel site within the core protein dimer-dimer interface, AB-836 inhibits pregenomic RNA encapsidation and blocks both viral replication and replenishment of covalently closed circular DNA (cccDNA), the persistent form of HBV genetic material in infected cells. AB-836 has demonstrated potent antiviral activity in vitro against wild-type HBV as well as variants resistant to nucleos(t)ide analogs and other capsid assembly modulators (CAMs). In clinical studies, it achieved significant reductions in serum HBV DNA levels after 28 days of once-daily oral dosing. The drug was initially developed by Arbutus Biopharma for chronic hepatitis B infection but its development was discontinued after Phase 1 trials due to safety findings that warranted further evaluation[1][3][5][6][8].

Other names

2445597-31-7MHY5H5WMW6MHY-5H5WMW6MHY 5H5WMW6CHEMBL5314907CHEMBL-5314907CHEMBL 5314907SCHEMBL22094191SCHEMBL-22094191SCHEMBL 22094191